Filgrastim is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by recombinant DNA technology. filgrastim is the Amgen Inc. trademark for Filgrastim‚ which has been selected as the name for recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF).
filgrastim is a 175 amino acid protein manufactured by recombinant DNA technology.1 filgrastim is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. filgrastim has a molecular weight of 18‚800 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because filgrastim is produced in E coli‚ the product is nonglycosylated and thus differs from G-CSF isolated from a human cell.
Filgrastim Injection is used in Cancer Patients Receiving Myelosuppressive Chemotherapy, Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy, Cancer Patients Receiving Bone Marrow Transplant, Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy, Patients With Severe Chronic Neutropenia